BridgeMD
A Phase 1/2a, Randomized, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of BJT-778 in Healthy Volunteers and in Subjects with Chronic Hepatitis B Infection, Including Subjects with Chronic Hepatitis D Infection
EU CTIS ID: 2022-502724-46-00
What this study is testing
To evaluate the safety and tolerability of BJT-778
- Phase I and Phase II (Integrated)- Other
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Cohorts B through F: Able and willing to provide written informed consent (signed and dated) and any authorizations required by local law and can comply with all study requirements
- Cohorts D and F only: Must have quantifiable HDV ribonucleic acid (RNA) levels
- Male or female adults between 18 and 70 years of age
- BMI 18 to 40 kg/m2
- Chronic HBV infection ≥6 months (eg, positive for serum HBsAg ≥6 months)
- Plasma HBV deoxyribonucleic acid (DNA) <100 IU/mL at Scree
You likely can't join if
- Cohorts B through F: Evidence of cirrhosis as determined by any of the following: o Liver biopsy (ie,Metavir Score F4) within 1 year of Screening, or o Fibroscan ≥10.8 Kpa within 1 year of Screening
- Screening laboratory results as follows, or any other clinically significant abnormalities in screening laboratory values that would render a subject unsuitable for inclusion: o ALT or aspartate aminotransferase (AST) >3× upper limit of normal (ULN) o Total bilirubin >1.2× ULN, except for subjects with Gilbert’s (normal direct bilirubin) o Serum albumin <3.5 g/dL o International normalized ratio (INR) >1.2 o Platelet count <140 k/mm3 o Hemoglobin <12.0 g/dL for males and <11.0 g/dL for females o Absolute neutrophil count <1500/mm3 o Estimated glomerular filtration rate (eGFR) <50 mL/min/1.73 m2 by Modification of Diet in Renal Disease II o Positive test for blood on urinalysis. In the event of a positive test, eligibility may be confirmed with urine microscopy showing <5 red blood cells per high power field
- Clinically significant abnormalities aside from chronic HBV infection in medical history (eg, previous acute coronary syndrome within 6 months of Screening, major surgery within 3 months of Screening, uncontrolled diabetes) or physical examination
- History of bleeding diathesis or coagulopathy
- History or suspected presence of vasculitis
- History of extrahepatic disorders possibly related to HBV immune complexes (eg, glomerulonephritis, polyarteritis nodosa)
See the full eligibility criteria
Who can join
- Cohorts B through F: Able and willing to provide written informed consent (signed and dated) and any authorizations required by local law and can comply with all study requirements
- Cohorts D and F only: Must have quantifiable HDV ribonucleic acid (RNA) levels
- Male or female adults between 18 and 70 years of age
- BMI 18 to 40 kg/m2
- Chronic HBV infection ≥6 months (eg, positive for serum HBsAg ≥6 months)
- Plasma HBV deoxyribonucleic acid (DNA) <100 IU/mL at Scree
- On nucleos(t)ide analogs (entecavir, tenofovir disoproxil, or tenofovir alafenamide) for at least 2 months and willing to remain on stable treatment for the duration of the study
- Quantitative HBsAg level criteria at Screening by cohort/group: o Cohort B: ≥10 to ≤3000 IU/mL o Cohort C: >3000 IU/mL o Cohort D: ≥10 IU/mL o Cohorts E and F: ≥10 IU/mL
- Females: Nonpregnant and nonlactating; surgically sterile (eg, tubal ligation, hysterectomy, bilateral salpingectomy, bilateral oophorectomy), postmenopausal (defined as 12 months of spontaneous amenorrhea in females >55 years of age or, in females ≤55 years of age, 12 months of spontaneous amenorrhea without an alternative medical cause and FSH levels in the postmenopausal range for the laboratory involved) or, if engaged in sexual relations and of childbearing potential, subject is using an acceptable contraceptive method from the time of signing the informed consent form until at least 12 weeks after the last dose of study drug.
- Males: Surgically sterile or, if engaged in sexual relations with a female of childbearing potential, subject is utilizing an acceptable contraceptive method during treatment with study drug and for at least 12 weeks after the last dose of study drug. Agree not to donate sperm for at least 12 weeks after the last dose of study drug.
What rules you out
- Cohorts B through F: Evidence of cirrhosis as determined by any of the following: o Liver biopsy (ie,Metavir Score F4) within 1 year of Screening, or o Fibroscan ≥10.8 Kpa within 1 year of Screening
- Screening laboratory results as follows, or any other clinically significant abnormalities in screening laboratory values that would render a subject unsuitable for inclusion: o ALT or aspartate aminotransferase (AST) >3× upper limit of normal (ULN) o Total bilirubin >1.2× ULN, except for subjects with Gilbert’s (normal direct bilirubin) o Serum albumin <3.5 g/dL o International normalized ratio (INR) >1.2 o Platelet count <140 k/mm3 o Hemoglobin <12.0 g/dL for males and <11.0 g/dL for females o Absolute neutrophil count <1500/mm3 o Estimated glomerular filtration rate (eGFR) <50 mL/min/1.73 m2 by Modification of Diet in Renal Disease II o Positive test for blood on urinalysis. In the event of a positive test, eligibility may be confirmed with urine microscopy showing <5 red blood cells per high power field
- Clinically significant abnormalities aside from chronic HBV infection in medical history (eg, previous acute coronary syndrome within 6 months of Screening, major surgery within 3 months of Screening, uncontrolled diabetes) or physical examination
- History of bleeding diathesis or coagulopathy
- History or suspected presence of vasculitis
- History of extrahepatic disorders possibly related to HBV immune complexes (eg, glomerulonephritis, polyarteritis nodosa)
- Malignancy within 5 years, except for basal or squamous cell carcinoma of the skin or carcinoma in situ of the cervix that has been successfully treated
- Treatment with a different investigational drug other than BJT-778, a biological agent or device within 4 weeks or 5 half-lives of Screening, whichever is longer
- History of excess alcohol consumption within 1 year of Screening, defined as weekly intake of ≥14 drinks per week (average of ≥2 drinks per day)
- History of drug abuse/addiction within 6 months of Screening (except cannabis) or a positive drug test at Screening (excluding physician-prescribed drugs and cannabis)
- Unwillingness to comply with study procedures, including follow up, as specified by this protocol, or unwillingness to cooperate fully with the Investigator
- History of decompensated liver disease as evidenced by ascites, hepatic encephalopathy, and/or gastric or esophageal varices
- Have any other conditions (medical, social, psychiatric, or other), which in the opinion of the Investigator would make the subject unsuitable for inclusion, or could interfere with the subject participating in or completing the study
- Positive rapid antigen test for COVID-19 on Study Day 1
- Cohorts B, C, and E only: Positive HDV Ab
- History of liver disease other than Hepatitis B (ie, nonalcoholic steatohepatitis, alcohol associated hepatitis, cholestatic liver disease, etc.)
- Chronic HCV infection; subjects with past HCV RNA infection that was successfully treated must be HCV RNA negative and at least 24 weeks post-treatment
- HIV infection (Cohorts B, C, and E); well-controlled HIV infection will be allowed in Cohorts D and F, defined as on antiretroviral therapy for at least 6 months and HIV RNA below the limit of quantification with a CD4 count ≥400 cells/mm3 at Screening
- Received solid organ or bone marrow transplant
- Currently taking, or took within 1 month of Screening, any immunosuppressive drugs (eg, prednisone). If the subject received a short course, the situation may be discussed with the Medical Monitor, or designee
- Diagnosed hepatocellular carcinoma (HCC) or suspected HCC as evidenced by screening alpha-fetoprotein ≥20 ng/mL
- History of hypersensitivity to any of the components in the BJT-778 formulation
The study team makes the final eligibility decision.
Where it's taking place
- Ukraine
- Australia
- Moldova, Republic of
- United Kingdom
- Korea, Republic of
- Hong Kong
- New Zealand
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18-64 years, 65+ years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Ukraine; Australia; Moldova, Republic of; United Kingdom; Korea, Republic of; Hong Kong and 1 more location(s). Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.